Glomeria Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Glomeria Therapeutics - overview
Location
-, -, Italy
Primary Industry
Pharmaceuticals
About
Glomeria Therapeutics is a biotechnology firm focused on advancing therapeutic solutions through innovative research and development in the health sector. Founded in Italy, Glomeria Therapeutics specializes in biotechnological solutions aimed at therapeutic advancements. The company has undergone strategic pivots to enhance its operations. As of September 2015, Glomeria raised EUR 1 million in VC funding from investors including Quadrivio, Vertis, Sofimac Partners, and Faro Capital, marking a significant investment target for these firms.
The company operates without known subsidiaries or parent companies. Glomeria Therapeutics is committed to developing therapeutic products that address various health conditions. Their services encompass research and development in biotechnology, focusing on novel treatments and enhancements to existing therapies. The company engages in collaborations with academic institutions and other organizations to foster innovation in healthcare solutions.
In the most recent financial year, Glomeria Therapeutics reported a revenue of EUR 25,519. 50 with an EBITDA of EUR -98,985. 20, reflecting the ongoing investment in research and development activities. Following the EUR 1 million funding round in September 2015, Glomeria Therapeutics aims to leverage these resources for expanding its product development pipeline.
The company plans to launch new therapeutic products targeting existing health challenges, with specific timelines yet to be disclosed. Additionally, Glomeria is exploring opportunities to expand its market presence beyond Italy into key European markets by 2018, aiming to enhance access to its innovative therapies.
Current Investors
Vertis, Lighthouse Venture Group, Sofimac Partners
Primary Industry
Pharmaceuticals
Sub Industries
Medical Devices & Equipment, Pharmaceutical Research & Development
Website
www.glomeria.com
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Glomeria Therapeutics - financials
| Fiscal Year Ended | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 |
|---|---|---|---|---|---|
| Revenue (USD) | - | 4,032 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - |
| EBITDA (USD) | (664,189) | (875,505) | - | - | - |
| Operating Income (USD) | (690,598) | (900,358) | - | - | - |
| Operating Margin | - | (22330.3%) | - | - | - |
| % EBITDA Margin | - | (21713.9%) | - | - | - |
| NET Income (USD) | (683,784) | (965,586) | - | - | - |
| % Net Margin | - | (23948.1%) | - | - | - |
Glomeria Therapeutics - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.